Searched for
GLENMARK PHARMACEUTICALS STOCKS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Capitalmind Flexi Cap Fund exits RIL and 2 others, hikes stake in Titan Company, MCX and 16 other stocks in AprilCapitalmind Flexi Cap Fund exited Reliance Industries, Bank of Baroda, and L&T Finance in April. The fund also increased stakes in Titan Co...
- GE Vernova among 7 mid-cap stocks that hit 52-week highs & rallied up to 30% in a monthDespite a 999-point drop in the BSE Sensex, seven BSE 150 midcap stocks hit 52-week highs, signalling strong momentum in select sectors, wi...
- Nifty finds support: Nagaraj Shetti spots 2 breakout stocks worth watchingNifty's Monday pullback is a technical dip, not a trend reversal, says HDFC Securities analyst Nagaraj Shetti. After forming a higher botto...
- Glenmark surges 20% after major drug licensing deal with AbbVieGlenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a ...
- I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300ICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals, revising the target price to Rs 1,300. The brokerage anticipates reve...
- Reduce Glenmark Pharmaceuticals, target price Rs 1,265: ICICI SecuritiesICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...
- Buy Glenmark Pharmaceuticals, target price Rs 1,779: Choice Equity BrokingChoice Equity Broking has issued a buy call for Glenmark Pharmaceuticals, setting a target price of Rs 1,779. The brokerage projects robust...
- Reduce Glenmark Pharmaceuticals, target price Rs 660: ICICI SecuritiesGlenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the y...
- Buy Glenmark Pharmaceuticals, target price Rs 619.8: ICICI DirectGlenmark Pharmaceuticals, incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 17229.19 Crore) operating in Pharm...
- Motilal Oswal Financial Services neutral on Glenmark Pharmaceuticals; target price: Rs 580Glenmark Pharmaceuticals, incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 17198.15 Crore) operating in Pharm...
- Glenmark Pharmaceuticals rises 5% on launching first 3-drug FDC for type-2 diabetes in India“This FDC has been launched under the brand name Zita®-PioMet,” the company said in a BSE filing. “This offers patients with Type 2 diabete...
- Buy Glenmark Pharmaceuticals, target price Rs 580: Nomura, IndiaGlenmark Pharmaceuticals, incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 12152.98 Crore) operating in Pharm...
- Stock Radar: This pharma company sees breakout after 6-month consolidation; time to buy?Short-term traders can look to buy the stock now or on dips for a possible target of Rs 474 in the next 4-6 weeks, suggested experts
- Hold Glenmark Pharmaceuticals, target price Rs 440: ICICI DirectGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 11075.10 Crore) operating in ...
- Glenmark Pharmaceuticals gains 7% on Q2 results; brokerages maintain buyThe company had posted a net profit of Rs 56.58 crore for the quarter ended September 30, 2011, Glenmark Pharmaceuticals said in a statemen...
- Glenmark surges 12% on BSE on Sanofi-Aventis licensing pactShares of pharma firm Glenmark Pharmaceuticals today vaulted by 12 per cent on the Bombay Stock Exchange to touch a year-high of Rs 303.80 ...
Load More
